Advertisement



Drug Shortages

Last updated

Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.

161 medicines

  • Fulvestrant Being discontinued 1 product · updated August 14, 2026

    Oncology

    Product Availability Expected supply / notes
    Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · August 14, 2026

    Uses, warnings and side effects from the FDA label →

  • Diclofenac Sodium Being discontinued 6 products · updated August 13, 2026

    Musculoskeletal, Rheumatology

    Product Availability Expected supply / notes
    Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-06)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026
    Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-96)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026
    Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-11)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026
    Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-06)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026
    Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-11)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026
    Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-96)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026

    Uses, warnings and side effects from the FDA label →

  • Polyethylene Glycol 3350 Being discontinued 1 product · updated August 13, 2026

    Gastroenterology

    Product Availability Expected supply / notes
    Plenvu, Oral Solution, KIT (NDC 65649-400-01)
    Salix Pharmaceuticals, a division of Bausch Health US, LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 13, 2026

    Uses, warnings and side effects from the FDA label →

  • Glyburide Being discontinued 4 products · updated August 10, 2026

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53)
    Sanofi-Aventis U.S. LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 10, 2026
    Diabeta, Tablet, 5 mg (NDC 0093-9364-10)
    Sanofi-Aventis U.S. LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 10, 2026
    Diabeta, Tablet, 5 mg (NDC 0093-9364-01)
    Sanofi-Aventis U.S. LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 10, 2026
    Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01)
    Sanofi-Aventis U.S. LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 10, 2026

    Uses, warnings and side effects from the FDA label →

  • Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Being discontinued 18 products · updated August 3, 2026

    Renal

    Product Availability Expected supply / notes
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-06)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0409-07)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0457-05)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-07)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-53)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-52)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-53)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-52)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0430-51)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-53)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0433-51)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-06)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-06)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-07)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-52)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0459-05)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-07)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
    DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0424-51)
    Vantive US Healthcare LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 3, 2026
  • Doxycycline Hyclate Being discontinued 4 products · updated July 30, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 30, 2026
    Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 30, 2026
    Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 12, 2026
    Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 12, 2026

    Uses, warnings and side effects from the FDA label →

  • Glycopyrrolate Being discontinued 4 products · updated July 30, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 30, 2026
    Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 30, 2026
    Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 30, 2026
    Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 30, 2026

    Uses, warnings and side effects from the FDA label →

  • Fluticasone Propionate and Salmeterol Xinafoate Being discontinued 3 products · updated July 27, 2026

    Pulmonary/Allergy

    Product Availability Expected supply / notes
    Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22)
    GlaxoSmithKline    		 The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
    Being discontinued · July 27, 2026
    Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22)
    GlaxoSmithKline    		 The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
    Being discontinued · July 27, 2026
    Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22)
    GlaxoSmithKline    		 The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.
    Being discontinued · July 27, 2026

    Uses, warnings and side effects from the FDA label →

  • Lopinavir and Ritonavir Being discontinued 5 products · updated July 24, 2026

    Antiviral

    Product Availability Expected supply / notes
    Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026
    Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026
    Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026
    Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026
    Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026

    Uses, warnings and side effects from the FDA label →

  • Ritonavir Being discontinued 2 products · updated July 24, 2026

    Antiviral

    Product Availability Expected supply / notes
    Norvir, Oral Powder, 100 mg (NDC 0074-3399-30)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026
    Norvir, Tablet, 100 mg (NDC 0074-2340-30)
    AbbVie Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 24, 2026

    Uses, warnings and side effects from the FDA label →

  • Aspirin Being discontinued 1 product · updated July 23, 2026

    Analgesia/Addiction, Cardiovascular

    Product Availability Expected supply / notes
    Aspirin, Suppository, 300 mg (NDC 0574-7034-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Atropa Belladonna and Opium Being discontinued 4 products · updated July 23, 2026

    Analgesia/Addiction

    Product Availability Expected supply / notes
    Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-04)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Bendamustine Hydrochloride Being discontinued 1 product · updated July 23, 2026

    Oncology

    Product Availability Expected supply / notes
    Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08)
    Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)    		 A business decision has been made to discontinue manufacture of the drug.
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Hydrocortisone Acetate Being discontinued 2 products · updated July 23, 2026

    Analgesia/Addiction, Other

    Product Availability Expected supply / notes
    Hydrocortisone Acetate, Suppository, 25 mg (NDC 0574-7090-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Hydrocortisone Acetate, Suppository, 30 mg (NDC 0574-7093-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Hydromorphone Hydrochloride Being discontinued 1 product · updated July 23, 2026

    Analgesia/Addiction

    Product Availability Expected supply / notes
    Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Morphine Sulfate Being discontinued 6 products · updated July 23, 2026

    Analgesia/Addiction

    Product Availability Expected supply / notes
    Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026
    Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11)
    Upsher-Smith Laboratories, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · December 22, 2025
    Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11)
    Upsher-Smith Laboratories, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · December 22, 2025

    Uses, warnings and side effects from the FDA label →

  • Podophyllum Resin Being discontinued 1 product · updated July 23, 2026

    Dermatology

    Product Availability Expected supply / notes
    Podocon 25, Topical Tincture, 1 mg/4 mL (NDC 0574-0601-15)
    Padagis US LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Succinylcholine Chloride Being discontinued 1 product · updated July 23, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Succinylcholine Chloride, Injection, 20 mg/1 mL (NDC 63323-943-10)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 23, 2026

    Uses, warnings and side effects from the FDA label →

  • Tobramycin Being discontinued 1 product · updated July 17, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)
    Hospira, Inc., a Pfizer Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 17, 2026

    Uses, warnings and side effects from the FDA label →

  • Travoprost Being discontinued 2 products · updated July 7, 2026

    Ophthalmology

    Product Availability Expected supply / notes
    Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 7, 2026
    Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · July 7, 2026

    Uses, warnings and side effects from the FDA label →

  • Desflurane Being discontinued 1 product · updated July 2, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Desflurane, Liquid for Inhalation, 240 mL/240 mL (NDC 0781-6172-86)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Discontinuation of the manufacture of the drug; Distributed by Sandoz, Inc.
    Being discontinued · July 2, 2026

    Uses, warnings and side effects from the FDA label →

  • Caspofungin Acetate Being discontinued 3 products · updated June 30, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026
    Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026
    Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 12, 2026

    Uses, warnings and side effects from the FDA label →

  • Daptomycin Being discontinued 2 products · updated June 30, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc.
    Being discontinued · June 30, 2026
    Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026

    Uses, warnings and side effects from the FDA label →

  • Gadobutrol Being discontinued 4 products · updated June 30, 2026

    Medical Imaging

    Product Availability Expected supply / notes
    Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-15)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
    Being discontinued · June 30, 2026
    Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-10)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
    Being discontinued · June 30, 2026
    Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-02)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
    Being discontinued · June 30, 2026
    Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-07)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA
    Being discontinued · June 30, 2026

    Uses, warnings and side effects from the FDA label →

  • Gadoterate Meglumine Being discontinued 8 products · updated June 30, 2026

    Medical Imaging

    Product Availability Expected supply / notes
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug
    Being discontinued · June 30, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 21, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 21, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 21, 2026
    Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 21, 2026

    Uses, warnings and side effects from the FDA label →

  • Oxaliplatin Being discontinued 4 products · updated June 29, 2026

    Oncology

    Product Availability Expected supply / notes
    Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
    Being discontinued · June 29, 2026
    Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10)
    Jiangsu Hengrui Pharmaceuticals Co., Ltd.    		 Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
    Being discontinued · June 29, 2026
    Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20)
    Fresenius Kabi USA, LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · February 25, 2026
    Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10)
    Fresenius Kabi USA, LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · February 25, 2026

    Uses, warnings and side effects from the FDA label →

  • Emtricitabine Being discontinued 2 products · updated June 17, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Emtriva, Capsule, 200 mg (NDC 61958-0601-1)
    Gilead Sciences, Inc.    		 Product expected to be available until March 2027
    Being discontinued · June 17, 2026
    Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1)
    Gilead Sciences, Inc.    		 Product expected to be available until March 2027
    Being discontinued · June 17, 2026

    Uses, warnings and side effects from the FDA label →

  • Lorlatinib Being discontinued 1 product · updated June 15, 2026

    Oncology

    Product Availability Expected supply / notes
    Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03)
    Pfizer Inc.    		 Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation
    Being discontinued · June 15, 2026

    Uses, warnings and side effects from the FDA label →

  • Memantine and Donepezil Being discontinued 2 products · updated June 15, 2026

    Neurology

    Product Availability Expected supply / notes
    Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3)
    Amneal Pharmaceuticals    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 15, 2026
    Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3)
    Amneal Pharmaceuticals    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 15, 2026

    Uses, warnings and side effects from the FDA label →

  • Dacomitinib Being discontinued 3 products · updated June 8, 2026

    Oncology

    Product Availability Expected supply / notes
    Vizimpro, Tablet, 15 mg (NDC 0069-0197-30)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 8, 2026
    Vizimpro, Tablet, 30 mg (NDC 0069-1198-30)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 8, 2026
    Vizimpro, Tablet, 45 mg (NDC 0069-2299-30)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · June 8, 2026

    Uses, warnings and side effects from the FDA label →

Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.

Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.

Advertisement